{"id":"https://openalex.org/W2102013071","doi":"https://doi.org/10.1080/004982597240767","title":"Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose","display_name":"Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose","publication_year":1997,"publication_date":"1997-01-01","ids":{"openalex":"https://openalex.org/W2102013071","doi":"https://doi.org/10.1080/004982597240767","mag":"2102013071","pmid":"https://pubmed.ncbi.nlm.nih.gov/9041679"},"language":"en","primary_location":{"id":"doi:10.1080/004982597240767","doi":"https://doi.org/10.1080/004982597240767","is_oa":false,"landing_page_url":"https://doi.org/10.1080/004982597240767","pdf_url":null,"source":{"id":"https://openalex.org/S48760969","display_name":"Xenobiotica","issn_l":"0049-8254","issn":["0049-8254","1366-5928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Xenobiotica","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5081304935","display_name":"Felix Waldmeier","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Waldmeier","raw_affiliation_strings":["Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, Basle, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, Basle, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018533252","display_name":"G\u00e9rard Flesch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"G. Flesch","raw_affiliation_strings":["Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","Novartis (Switzerland), Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Novartis (Switzerland), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013773487","display_name":"P. Mu \u0308ller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"P. Mu Ller","raw_affiliation_strings":["Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","Novartis (Switzerland), Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Novartis (Switzerland), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033883089","display_name":"T. WINKLER","orcid":"https://orcid.org/0009-0008-2483-8488","observed_orcids":["https://orcid.org/0009-0008-2483-8488"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"T. Winkler","raw_affiliation_strings":["Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","Novartis (Switzerland), Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Novartis (Switzerland), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052725832","display_name":"H.\u2010P. KRIEMLER","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"H.- P. Kriemler","raw_affiliation_strings":["Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","Novartis (Switzerland), Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Novartis (Switzerland), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019242756","display_name":"Peter B\u00fchlmayer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"P. Buhlmayer","raw_affiliation_strings":["Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","Novartis (Switzerland), Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Novartis (Switzerland), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5055155293","display_name":"Marc de Gasparo","orcid":"https://orcid.org/0000-0002-1005-7866","observed_orcids":["https://orcid.org/0000-0002-1005-7866"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"M. De Gasparo","raw_affiliation_strings":["Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","Novartis (Switzerland), Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharma Research, Preclinical Safety, Drug Metabolism & Exploratory Toxicology Ciba-Geigy, CH-4002 Basle, Switzerland Pharma Research, Bioanalytics & Pharmacokinetics Ciba-Geigy, CH- 4002 Basle, Switzerland Pharma Medicine & Clinical Development Department, Human Pharmacology Ciba- Geigy, CH- 4002 Basle, Switzerland . Physics Department, Spectroscopy Ciba-Geigy, CH- 4002 Basle, Switzerland s Pharma Research Ciba-Geigy, CH-4002 Basle, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Novartis (Switzerland), Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.826,"has_fulltext":false,"cited_by_count":133,"citation_normalized_percentile":{"value":0.93917892,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"27","issue":"1","first_page":"59","last_page":"71"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7261000275611877,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7261000275611877,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.24050000309944153,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12910","display_name":"Eicosanoids and Hypertension Pharmacology","score":0.007499999832361937,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valsartan","display_name":"valsartan","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9570000171661377},{"id":"https://openalex.org/keywords/drug-disposition","display_name":"drug disposition","score":0.6480000019073486},{"id":"https://openalex.org/keywords/biotransformation","display_name":"biotransformation","score":0.9139999747276306},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9070000052452087},{"id":"https://openalex.org/keywords/oral-absorption","display_name":"oral absorption","score":0.4650000035762787},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.8109999895095825},{"id":"https://openalex.org/keywords/fecal-excretion","display_name":"fecal excretion","score":0.7889999747276306},{"id":"https://openalex.org/keywords/biliary-excretion","display_name":"biliary excretion","score":0.699999988079071},{"id":"https://openalex.org/keywords/oxidative-metabolism","display_name":"oxidative metabolism","score":0.8159999847412109},{"id":"https://openalex.org/keywords/radiolabeled-drug","display_name":"radiolabeled drug","score":0.7730000019073486}],"concepts":[{"id":"https://openalex.org/C2777387769","wikidata":"https://www.wikidata.org/wiki/Q155472","display_name":"Valsartan","level":3,"score":0.9319697022438049},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.8073013424873352},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7631198167800903},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.7503936290740967},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5820751190185547},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.5382888317108154},{"id":"https://openalex.org/C10146269","wikidata":"https://www.wikidata.org/wiki/Q185557","display_name":"Excretion","level":2,"score":0.5146442651748657},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.466448038816452},{"id":"https://openalex.org/C3941253","wikidata":"https://www.wikidata.org/wiki/Q47270","display_name":"Half-life","level":3,"score":0.4249117970466614},{"id":"https://openalex.org/C27881333","wikidata":"https://www.wikidata.org/wiki/Q864895","display_name":"Biotransformation","level":3,"score":0.4176935851573944},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3649495244026184},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.1677541732788086},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09775543212890625},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068756","descriptor_name":"Valsartan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000652","qualifier_name":"urine","is_major_topic":false},{"descriptor_ui":"D001711","descriptor_name":"Biotransformation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002250","descriptor_name":"Carbon Radioisotopes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005243","descriptor_name":"Feces","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D005470","descriptor_name":"Fluorometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011945","descriptor_name":"Receptors, Angiotensin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000652","qualifier_name":"urine","is_major_topic":false},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D014633","descriptor_name":"Valine","qualifier_ui":"Q000652","qualifier_name":"urine","is_major_topic":false},{"descriptor_ui":"D044140","descriptor_name":"Receptor, Angiotensin, Type 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057911","descriptor_name":"Angiotensin Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/004982597240767","doi":"https://doi.org/10.1080/004982597240767","is_oa":false,"landing_page_url":"https://doi.org/10.1080/004982597240767","pdf_url":null,"source":{"id":"https://openalex.org/S48760969","display_name":"Xenobiotica","issn_l":"0049-8254","issn":["0049-8254","1366-5928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Xenobiotica","raw_type":"journal-article"},{"id":"pmid:9041679","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9041679","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Xenobiotica; the fate of foreign compounds in biological systems","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W1543348686","https://openalex.org/W1936333617","https://openalex.org/W1971598858","https://openalex.org/W1972212193","https://openalex.org/W1990168476","https://openalex.org/W2030755374","https://openalex.org/W2061743585","https://openalex.org/W2065142189","https://openalex.org/W2087918383","https://openalex.org/W2090175582","https://openalex.org/W2092171289","https://openalex.org/W2097712021","https://openalex.org/W2106245429","https://openalex.org/W2128635872","https://openalex.org/W2151543409","https://openalex.org/W2152852886","https://openalex.org/W2167541943","https://openalex.org/W2336891920","https://openalex.org/W2521909351","https://openalex.org/W2617943469","https://openalex.org/W4242406743","https://openalex.org/W4244098017"],"related_works":["https://openalex.org/W2092789823","https://openalex.org/W2064823654","https://openalex.org/W1488468950","https://openalex.org/W2288736430","https://openalex.org/W2036918345","https://openalex.org/W2101817712","https://openalex.org/W6963662302","https://openalex.org/W2149292566","https://openalex.org/W1972212193","https://openalex.org/W13032222"],"abstract_inverted_index":{"1.":[0],"The":[1,56,151,161,197],"disposition":[2],"of":[3,25,28,40,54,58,71,86,95,114,143,147,153,172,181,191,224],"valsartan,":[4],"a":[5,21,29,33,103,112],"potent":[6],"angiotensin":[7],"II":[8],"receptor":[9],"antagonist,":[10],"was":[11,74,78,90,126,156,176,184,213],"investigated":[12],"in":[13,44,83,128,194,227],"six":[14],"healthy":[15],"male":[16],"volunteers.":[17],"They":[18],"each":[19],"received":[20],"single":[22],"oral":[23],"dose":[24,73,155,193,226],"80":[26],"mg":[27],"14C-labelled":[30],"preparation":[31],"as":[32],"neutral":[34],"buffered":[35],"solution.":[36],"2.":[37],"Peak":[38],"concentrations":[39],"radioactivity":[41,89,108],"and":[42,88,92,218],"valsartan":[43,87],"plasma":[45,130,148],"measured":[46],"1":[47,98],"h":[48,99,137],"after":[49,138],"dosing":[50],"showed":[51],"rapid":[52],"onset":[53],"absorption.":[55],"results":[57],"this":[59],"study":[60],"combined":[61],"with":[62,111],"other":[63],"available":[64],"data":[65],"indicate":[66],"that":[67],"at":[68,131],"least":[69],"51%":[70],"the":[72,79,129,144,154,192,195,225,228],"absorbed.":[75],"3.":[76],"Valsartan":[77,183],"predominant":[80,177,198],"radioactive":[81],"compound":[82],"plasma.":[84],"Elimination":[85],"fast":[91],"multiexponential.":[93],"beta-Half-lives":[94],"6":[96],"+/-":[97,116,170,179,189,222],"were":[100],"observed.":[101],"In":[102],"terminal":[104],"elimination":[105,205],"phase,":[106],"low":[107],"levels":[109],"decreased":[110],"half-life":[113],"81":[115],"33":[117],"h.":[118],"A":[119],"minor,":[120],"pharmacologically":[121],"inactive":[122,210],"metabolite":[123],"(valeryl-4-hydroxy-valsartan;":[124],"M1)":[125],"detected":[127],"time":[132],"points":[133],"later":[134],"than":[135],"2":[136],"dosing,":[139],"representing":[140],"approximately":[141],"11%":[142],"AUC(24":[145],"h)":[146],"radioactivity.":[149],"4.":[150],"bulk":[152],"excreted":[157,186],"within":[158,164],"4":[159],"days.":[160],"total":[162],"excretion":[163,175],"7":[165],"days":[166],"amounted":[167],"to":[168,202],"99":[169],"1%":[171],"dose.":[173],"Faecal":[174],"(86":[178],"5%":[180,190],"dose).":[182],"largely":[185],"unchanged":[187],"(81":[188],"excreta).":[196],"clearance":[199],"mechanism":[200],"appeared":[201],"be":[203],"direct":[204],"via":[206],"bile.":[207],"5.":[208],"An":[209],"metabolite,":[211],"M1,":[212],"formed":[214],"by":[215],"oxidative":[216],"biotransformation":[217],"accounted":[219],"for":[220],"9":[221],"3%":[223],"excreta.":[229]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":5},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":8}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}